Literature DB >> 7041729

Danazol.

A E Madanes, M Farber.   

Abstract

Danazol, approved 5 years ago for the treatment of pelvic endometriosis, has recently been approved for treating cystic disease of the breast. As the mechanisms of action of this drug are made clear, the clinical syndromes that can be treated by this impeded androgen have increased dramatically. Results of controlled prospective clinical studies on the drug have increased our understanding of the pathophysiology of several poorly understood diseases. Danazol is well tolerated by most patients; the side effects are mild and reversible.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7041729     DOI: 10.7326/0003-4819-96-5-625

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  5 in total

1.  Danazol induced pancreatitis and hepatitis.

Authors:  X Chevalier; H Awada; A Baetz; B Amor
Journal:  Clin Rheumatol       Date:  1990-06       Impact factor: 2.980

2.  Vitamin D metabolites and analogues, diphosphonates, danazol, and bromocriptine.

Authors:  C R Paterson; J Feely
Journal:  Br Med J (Clin Res Ed)       Date:  1983-05-21

Review 3.  Danazol in non-splenectomized patients with refractory idiopathic thrombocytopenic purpura.

Authors:  D Z Edelmann; B Knobel; I Virag; D Meytes
Journal:  Postgrad Med J       Date:  1990-10       Impact factor: 2.401

4.  Tamoxifen and fluoxymesterone versus tamoxifen and danazol in metastatic breast cancer--a randomized study.

Authors:  S M Swain; S M Steinberg; C Bagley; M E Lippman
Journal:  Breast Cancer Res Treat       Date:  1988-09       Impact factor: 4.872

5.  Small bowel endometriosis masquerading as regional enteritis.

Authors:  A Minocha; M S Davis; R A Wright
Journal:  Dig Dis Sci       Date:  1994-05       Impact factor: 3.199

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.